Physician profile
Benjamin E Nissley
NPI 1023565132
$1,264.95
in general payments reported to CMS, 2019-2025
18 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2023: $216 · 2024: $404 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.23 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $220.97 | 2023-2025 | |
| Abbvie INC. | $137.10 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.12 | 2023-2025 | Caplyta |
| Esperion Therapeutics, INC. | $123.60 | 2021 | |
| Neurocrine Biosciences, INC. | $93.97 | 2024 | Ingrezza |
| Novo Nordisk INC | $88.78 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $76.77 | 2023-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $70.92 | 2021 | |
| Pfizer INC. | $64.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.73 | 2025 | Airsupra |
| Abbott Laboratories | $44.56 | 2024 | Id Now Instrument, Freestyle Libre 3 |
| Exact Sciences Corporation | $32.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $32.58 | 2021 | |
| Ani Pharmaceuticals, INC. | $25.96 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $19.24 | 2025 | Gardasil 9, Vaxneuvance, Enflonsia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.97 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $15.73 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $15.57 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Nissley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.